Real-world Treatment Patterns and Associated Outcomes in Patients With Resectable Early-stage Non-small Cell Lung Cancer

Trial Identifier: D133FR00169
Sponsor: AstraZeneca
NCTID:: NCT04808050
Start Date: November 2021
Primary Completion Date: October 2022
Study Completion Date: October 2022
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Australia, NSW Sydney, NSW, Australia
Australia, QLD Brisbane, QLD, Australia
Australia, WA Perth, WA, Australia
Egypt, Egypt Alexandria, Egypt, Egypt
Egypt, Egypt Cairo, Egypt, Egypt
Egypt, Egypt Sohag, Egypt, Egypt
Hong Kong, Hong Kong Hong Kong, Hong Kong
India, India Bangalore, India, India, 560017
India, India Delhi, India, India, 110005
India, India Faridabad, India, India, 121001
India, India Howrah, Kolkata, India, India, 711103
India, India Kolkata, India, India, 700160
India, India Mumbai, India, India, 400615
India, India Mumbai, India, India, 400012
India, India Mumbai, India, India, 400036
India, India New Delhi, India, India, 110017
Kuwait, Kuwait Kuwait City, Kuwait, Kuwait
Turkey, Turkey Adana, Turkey, Turkey
Turkey, Turkey Ankara, Turkey, Turkey
Turkey, Turkey Antalya, Turkey, Turkey
Turkey, Turkey Diyarbakir, Turkey, Turkey
Turkey, Turkey Istanbul, Turkey, Turkey
Turkey, Turkey Izmir, Turkey, Turkey
Turkey, Turkey Samsun, Turkey, Turkey
United Arab Emirates, United Arab Emirates Alain, United Arab Emirates, United Arab Emirates